Remternetug Phase 3 Alzheimer's Trial (NCT06653153)

Migration, Crosslink

📖

Remternetug Phase 3 Alzheimer's Trial (NCT06653153)

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct06653153

📖 Wiki Page

clinical2970 wordssynced 2026-04-02

Remternetug (LY3372993) Phase 3 Trial in Early Alzheimer's Disease

Overview

flowchart TD clinical_trials_nct06653153["Remternetug Phase 3 Alzheimers Trial NCT066531"] style clinical_trials_nct06653153 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_0["Trial Details"] clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_0 style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_nct0_1["Mechanism of Action"] clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_1 style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_nct0_2["Novel Ig-LLY Antibody Platform"] clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_2 style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_nct0_3["Amyloid Clearance Mechanism"] clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_3 style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_nct0_4["Comparison to Other Anti-Amyloid Antibodies"] clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_4 style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_5["Scientific Rationale"] clinical_trials_nct06653153 -->|"includes"| clinical_trials_nct0_5 style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000

...

Remternetug (LY3372993) Phase 3 Trial in Early Alzheimer's Disease

Overview

Mermaid diagram (expand to render)

The TRAILRUNNER-ALZ 3 study (NCT06653153) is a pivotal Phase 3 clinical trial evaluating remternetug (LY3372993), an innovative amyloid-targeting immunotherapy developed by Eli Lilly and Company, in patients with early Alzheimer's disease. This trial represents a significant advancement in the development of disease-modifying treatments for Alzheimer's disease, building upon the lessons learned from previous amyloid-targeting antibodies including lecanemab and donanemab["@trailrunner"][@remt2024].

Remternetug is a novel Ig-LLY antibody that targets a unique conformation of amyloid-beta plaques, potentially offering improved efficacy and safety compared to earlier-generation antibodies. The trial aims to demonstrate whether remternetug can slow cognitive and functional decline in patients with early-stage Alzheimer's disease, potentially establishing a new treatment paradigm for this devastating disease["@amyloid2024"].

Trial Details

| Parameter | Details |
|-----------|---------|
| NCT Number | NCT06653153 |
| Phase | Phase 3 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Eli Lilly and Company |
| Enrollment | 1,400 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | October 24, 2024 |
| Completion Date | October 1, 2030 |
| Last Updated | November 20, 2025 |

Mechanism of Action

Novel Ig-LLY Antibody Platform

Remternetug (LY3372993) represents a new generation of amyloid-targeting antibodies utilizing a distinctive Ig-LLY format. This innovative antibody design offers several potential advantages over traditional IgG antibodies[@remt2024]:

Enhanced Target Binding: The Ig-LLY format may provide improved binding affinity to amyloid-beta plaques

Unique Epitope Recognition: The antibody targets a specific conformation of aggregated amyloid-beta

Optimized Pharmacokinetics: The modified Fc region may improve brain penetration and retention

Reduced Off-Target Effects: Designed to minimize binding to normal brain proteins

Amyloid Clearance Mechanism

Remternetug works through the established amyloid clearance mechanism shared by successful anti-amyloid antibodies:

Binding to Amyloid Plaques: The antibody binds to aggregated amyloid-beta in the brain

Microglial Activation: Antibody-bound plaques are recognized by microglia via Fc receptors

Plaque Clearance: Activated microglia phagocytose and clear the amyloid deposits

Reduced Amyloid Burden: PET imaging demonstrates reduced amyloid plaque levels

Downstream Effects: Reduced amyloid leads to decreased tau pathology, neuroinflammation, and neurodegeneration

Comparison to Other Anti-Amyloid Antibodies

Remternetug builds upon the foundations established by previous amyloid-targeting antibodies:

| Antibody | Developer | Key Features | Approval Status |
|----------|-----------|---------------|------------------|
| Lecanemab | Eisai/Biogen | Protofibril-selective | Approved (2023) |
| Donanemab | Eli Lilly | N-terminal plaque targeting | Approved (2024) |
| Remternetug | Eli Lilly | Ig-LLY format, novel epitope | Phase 3 |

Scientific Rationale

Amyloid Cascade Hypothesis

The amyloid cascade hypothesis remains the dominant framework for understanding Alzheimer's disease pathogenesis. According to this model, accumulation of amyloid-beta peptide in the brain initiates a cascade of downstream events including tau hyperphosphorylation, neuroinflammation, synaptic loss, and ultimately neuronal death[@amyloid Cascade2024]. The updated hypothesis acknowledges that:

Amyloid accumulation begins decades before clinical symptoms
Different amyloid conformations may have varying pathogenicity
Amyloid removal may need to occur early in the disease process
Residual amyloid despite treatment may drive ongoing pathology

Evidence from Previous Anti-Amyloid Trials

The success of lecanemab and donanemab in Phase 3 trials has validated the amyloid-targeting approach[@lecanemab2023][@donanemab2024]:

Lecanemab (CLARITY-AD):

27% slowing of cognitive decline on CDR-SB at 18 months
Significant reduction in amyloid burden
ARIA-E (brain edema) in 12.6% of treatment group

Donanemab (TRAILBLAZER-ALZ 2):

36% slowing of cognitive decline on iADRS at 18 months
35% slowing on CDR-SB
Significant amyloid plaque reduction
ARIA-E in 24% of treatment group (higher with apoE4 carriers)

Remternetug aims to improve upon these results through its novel antibody design.

Importance of Early Intervention

The TRAILRUNNER-ALZ 3 trial specifically enrolls patients with early Alzheimer's disease, reflecting the understanding that:

Amyloid-Tau Relationship: Amyloid accumulation drives tau pathology; earlier amyloid removal may prevent downstream effects

Neurodegeneration Timeline: Significant neurodegeneration has already occurred by the time of clinical diagnosis

Treatment Window: The greatest benefit is expected in patients with preserved brain structure

Clinical Outcome Sensitivity: Earlier-stage patients show clearer treatment effects on functional measures

Study Design

Phase 3 Randomized Structure

The TRAILRUNNER-ALZ 3 trial employs a rigorous randomized, double-blind, placebo-controlled design:

Enrollment: 1,400 participants with early AD
Randomization: 1:1 ratio to remternetug or placebo
Blinding: Double-blind (participants and investigators unaware of assignment)
Duration: Up to 76 weeks (approximately 1.5 years)
Dosing: Monthly intravenous infusions

Treatment Arms

Remternetug Arm: Active treatment with Ig-LLY antibody

Placebo Arm: Matching vehicle solution

Key Design Features

Early AD Population: Confirmed early-stage Alzheimer's disease
Biomarker Confirmation: Amyloid positivity required via PET or CSF
Fixed Dose: Pre-specified dosing regimen
Safety Monitoring: Regular assessments for adverse events, particularly ARIA

Patient Population

Target Population

The trial enrolls patients with early Alzheimer's disease who meet the following criteria:

Diagnosis: Mild cognitive impairment due to AD or mild dementia due to AD
Age: Typically 50-85 years
Cognitive Status: MMSE 20-30 (mild impairment)
Amyloid Status: Confirmed amyloid positivity

Inclusion Criteria

Age 50-85 years

Meet NIA-AA criteria for MCI due to AD or mild AD dementia

Confirmed amyloid pathology via PET or CSF biomarkers

CDR global score of 0.5 or 1.0

MMSE score 20-30

Ability to complete all study procedures

Caregiver availability for study participation

Exclusion Criteria

History of stroke or significant cerebrovascular disease

Active neurological conditions other than AD

Psychiatric conditions that could interfere with assessment

Contraindications to MRI or PET imaging

Previous anti-amyloid antibody treatment

Significant medical conditions that could affect participation

Primary and Secondary Endpoints

Primary Endpoint

Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rating Scale (CDR)

The CDR is a validated instrument that assesses cognitive and functional impairment across six domains:

Memory
Orientation
Judgment and Problem Solving
Community Affairs
Home and Hobbies
Personal Care

A "clinically meaningful progression" is typically defined as:

CDR global score progression from 0.5 to 1.0 or higher
Or CDR sum of boxes increase of ≥1 point sustained over 12 weeks

The use of time-to-event analysis provides a sensitive measure of treatment effect[@cdr2023].

Secondary Endpoints

Cognitive Measures

ADAS-Cog14: 14-item Alzheimer's Disease Assessment Scale-Cognitive
MMSE: Mini-Mental State Examination
RAVLT: Rey Auditory Verbal Learning Test

Functional Measures

ADCS-ADL: Alzheimer's Disease Cooperative Study-Activities of Daily Living
FAQ: Functional Activities Questionnaire

Biomarker Measures

Amyloid PET: Regional and global amyloid SUVr change
Tau PET: Regional tau accumulation
CSF biomarkers: Aβ42/40, p-tau, total tau

Safety and Tolerability

Incidence and severity of ARIA (amyloid-related imaging abnormalities)
Treatment-emergent adverse events
Laboratory parameters

Clinical Significance

Advancing AD Treatment Landscape

The TRAILRUNNER-ALZ 3 trial represents a critical step in the development of next-generation anti-amyloid therapies:

Novel Mechanism: Ig-LLY antibody format may offer improved efficacy

Competitive Landscape: Results will inform positioning against lecanemab and donanemab

Patient Choice: Multiple effective options will benefit patients and physicians

Pipeline Continuation: Eli Lilly's commitment to AD treatment development

Potential Impact on AD Care

Successful results from this trial could:

Expand Treatment Options: Provide an additional amyloid-targeting therapy

Improve Outcomes: Potentially superior efficacy compared to existing options

Inform Precision Medicine: Biomarker data may identify optimal responders

Validate Ig-LLY Platform: Support development of next-generation antibodies

Regulatory Considerations

The trial is designed to support potential regulatory approval:

Pivotal Phase 3 design with FDA and EMA input
Established endpoints with precedent from lecanemab/donanemab
Biomarker substudies to support mechanistic understanding
Long-term safety follow-up planned

Biomarker Substudies

Amyloid PET Imaging

Quantitative amyloid PET imaging is performed to:

Confirm baseline amyloid positivity
Quantify amyloid plaque reduction with treatment
Correlate amyloid removal with clinical outcomes
Identify thresholds associated with clinical benefit

Tau PET Imaging

Tau PET assesses:

Baseline tau burden
Treatment effects on tau accumulation
Relationship between amyloid reduction and tau modulation

CSF Biomarker Program

Cerebrospinal fluid collections enable:

Aβ42/40 ratio changes
Phosphorylated tau (p-tau) and total tau
Neurodegeneration markers (NfL)
Exploration of treatment response biomarkers

Safety Profile Considerations

ARIA is the primary safety consideration for anti-amyloid antibodies:

ARIA-E (Edema):

Brain edema detected on MRI
Typically asymptomatic, but can cause headache, confusion, dizziness
More common with higher amyloid burden and apoE4 carriers
Management: temporary treatment discontinuation, monitoring

ARIA-H (Hemorrhage):

Microhemorrhages or superficial siderosis
Usually asymptomatic
Risk increased with anticoagulation

Monitoring Strategy

The trial includes:

Baseline MRI before treatment initiation
Regular MRI monitoring (weeks 4, 12, 24, 52, 76)
Clinical monitoring for ARIA symptoms
MRI reader training for consistent interpretation

Comparison to Anti-Amyloid Therapeutic Landscape

The development of remternetug occurs within the broader context of anti-amyloid antibody development:

Timeline of Anti-Amyloid Antibodies

Bapineuzumab (2007-2012): First-generation antibody - no clinical benefit

Solanezumab (2012-2023): Mixed results in Phase 3 - modest benefit in prodromal

Lecanemab (2023): First approved anti-amyloid antibody - 27% slowing

Donanemab (2024): Second approved - 36% slowing

Remternetug (ongoing): Third-generation - aims to improve further

Competitive Positioning

If approved, remternetug will compete with:

Lecanemab (Leqembi): Marketed by Eisai/Biogen, available in US, EU, Japan
Donanemab (Kisunla): Marketed by Eli Lilly, available in US

The Ig-LLY format and novel epitope may offer differentiation:

Potentially improved efficacy
Different safety profile
Convenience advantages

Regulatory History and Development Timeline

Preclinical Development

The development of remternetug followed a systematic approach:

Discovery Phase (2018-2020):

Identification of novel Ig-LLY antibody format
Epitope mapping against various Aβ conformations
In vitro characterization of binding properties
Lead optimization for brain penetration

Preclinical Testing (2020-2022):

Toxicology studies in non-human primates
PK/PD studies demonstrating brain exposure
Biodistribution studies confirming target engagement
Pilot efficacy studies in AD mouse models

Clinical Development

Phase 1 Studies (2022-2023):

First-in-human study establishing safety
Dose-escalation to determine optimal dose
PET imaging substudy confirming amyloid binding
CSF biomarker studies demonstrating target engagement

Phase 2 Study (2023-2024):

Dose-confirmatory study in early AD
Multiple dose levels evaluated
Biomarker endpoints confirming mechanism
Selection of Phase 3 dose

Regulatory Interactions

Eli Lilly has engaged with regulatory authorities throughout development:

FDA: Breakthrough Therapy Designation granted
EMA: PRIME designation awarded
PMDA: Sakigake designation in Japan

These designations reflect the potential for remternetug to address unmet needs in AD treatment.

Patient Journey and Trial Experience

Screening Process

The screening process for TRAILRUNNER-ALZ 3 involves:

Initial Assessment (Week -4 to -2):

Medical history and physical examination
Cognitive screening (MMSE, CDR)
Review of inclusion/exclusion criteria

Diagnostic Confirmation (Week -2 to 0):

Amyloid PET scan or CSF analysis
Tau PET scan (for some participants)
MRI brain imaging

Baseline Evaluation (Week 0):

Comprehensive cognitive testing
Functional assessments
Laboratory tests
Randomization

Treatment Phase

Infusion Schedule:

Monthly intravenous infusions
60-90 minute infusion time
Observation period post-infusion
Flexible scheduling for participants

Monitoring Visits:

Weeks 4, 12, 24, 52, 76
MRI at each key timepoint
Cognitive and functional assessments
Safety monitoring

Caregiver Involvement

The trial emphasizes caregiver participation:

Caregiver presence at infusions encouraged
Caregiver completing functional assessments
Caregiver monitoring for side effects
Support resources provided

Challenges and Mitigation Strategies

ARIA Management

ARIA remains a key challenge for anti-amyloid antibodies:

Detection Strategy:

Baseline MRI before first dose
MRI at weeks 4, 12, 24, 52, 76
Symptom-driven additional imaging
Central reading for consistency

Management Protocol:

Asymptomatic ARIA-E: Continue treatment with closer monitoring
Symptomatic ARIA-E: Temporary discontinuation, restart at lower dose
ARIA-H: Evaluate severity, may require treatment discontinuation

Risk Mitigation:

ApoE4 carrier status identified at screening
Higher-risk patients monitored more closely
Lower initial dose for carriers
Patient education on symptoms

Recruitment Challenges

The trial faces typical AD trial recruitment challenges:

Strategies to Enhance Recruitment:

Partnership with Alzheimer's Association trial finder
Community outreach and awareness campaigns
Collaboration with memory clinics and neurologists
Digital recruitment through patient registries

Retention Strategies

Maintaining participant engagement throughout the trial:

Regular contact between visits
Travel reimbursement for site visits
Flexible scheduling
Caregiver support resources
Compensation for time commitment

Health Economics and Access Considerations

Cost-Effectiveness Framework

If approved, remternetug will be evaluated for cost-effectiveness:

ICER Thresholds:

US: $50,000-$150,000/QALY typically considered acceptable
UK: £20,000-£30,000/QALY (NICE threshold)
EU: Varies by country

Model Parameters:

Treatment effect magnitude
Disease progression rate modification
Quality of life impacts
Healthcare resource utilization

Access and Reimbursement

Several factors will influence access:

US Market:

Medicare coverage decisions
Commercial insurance formularies
Patient assistance programs

International Markets:

Country-specific HTA evaluations
Pricing negotiations
formulary inclusion

Future Development Plans

Potential Indications

Beyond the TRAILRUNNER-ALZ 3 trial, Eli Lilly is exploring:

Preclinical AD:

Prevention trials in amyloid-positive cognitively normal individuals
Earlier intervention potentially more effective

Combination Approaches:

Combination with anti-tau antibodies
Combination with symptomatic agents
Personalized medicine approaches

Next-Generation Development

The Ig-LLY platform enables further innovation:

Enhanced brain penetration
Improved effector function
Bispecific antibody formats
Novel delivery mechanisms

Real-World Evidence Generation

Post-Marketing Surveillance

After potential approval, robust monitoring will continue:

Phase 4 studies in diverse populations
Registry-based safety monitoring
Effectiveness studies in routine clinical practice
Comparative effectiveness vs. other anti-amyloid agents

Patient Registry

Potential establishment of treatment registry:

Long-term safety follow-up
Biomarker correlation with outcomes
Quality of life tracking
Healthcare resource utilization

Comparison with Symptomatic Treatments

Mechanism Comparison

| Treatment Type | Mechanism | Effect | Disease Modification |
|---------------|-----------|--------|---------------------|
| Anti-amyloid antibodies | Remove Aβ plaques | Slows progression | Yes (demonstrated) |
| Cholinesterase inhibitors | Increase ACh | Symptomatic improvement | No |
| Memantine | NMDA modulation | Symptomatic improvement | No |
| Combination therapy | Multi-target | Both symptomatic and disease-modifying | Potential |

Complementary Approaches

Remternetug could potentially be combined with:

Cholinesterase inhibitors for symptomatic benefit
Anti-tau antibodies for downstream effect
Neuroprotective agents
Lifestyle interventions

Long-Term Vision

Alzheimer's Disease Treatment Landscape

Remternetug represents part of a evolving treatment landscape:

Current State (2025):

Two approved anti-amyloid antibodies
Symptomatic treatments available
No cure or prevention

Near-Term Vision (2027-2030):

Multiple anti-amyloid options
Combination approaches emerging
Biomarker-guided personalization
Earlier intervention emphasis

Long-Term Vision (2030+):

Preventive therapies for at-risk individuals
Multi-target combinations
Personalized medicine based on biomarkers
Potential disease modification or reversal

Remternetug's Place in This Vision

As a third-generation anti-amyloid antibody, remternetug aims to:

Improve upon first-generation efficacy
Offer alternative safety profile
Enable combination approaches
Contribute to understanding of optimal AD treatment

Clinical Trials

[Lecanemab CLARITY-AD Trial](/clinical-trials/lecanemab-clarity-ad)
[Donanemab TRAILBLAZER-ALZ 2](/clinical-trials/donanemab-trailblazer-alz-2)
[Drug Development Pipeline](/clinical-trials/drug-pipeline)
[Solanezumab A4 Study](/clinical-trials/solanezumab-a4)

Mechanisms

[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
[Amyloid-Beta Aggregation](/mechanisms/amyloid-beta-aggregation)
[Amyloid-Tau Interaction](/mechanisms/amyloid-tau-interaction)
[Anti-Amyloid Immunotherapy Mechanism](/mechanisms/anti-amyloid-immunotherapy-mechanism)

Proteins

[Amyloid Beta](/proteins/amyloid-beta)
[APP](/proteins/app)
[Tau Protein](/proteins/tau)
[ApoE](/proteins/apoe-protein)

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
[Amyloid-Related Imaging Abnormalities](/diseases/aria)

Therapeutics

[Anti-Amyloid Antibodies Overview](/therapeutics/anti-amyloid-antibodies-overview)
[Alzheimer's Disease Treatment Landscape](/therapeutics/alzheimers-disease-treatment-landscape)

Impact on the Field

Shift in AD Treatment Paradigm

The development of remternetug reflects a broader transformation in how Alzheimer's disease is approached:

From Symptomatic to Disease-Modifying:

Prior treatments addressed symptoms without affecting disease progression
Anti-amyloid antibodies demonstrate disease modification
Pipeline expanding with multiple mechanisms in development

From Single-Target to Multi-Target:

Recognition that AD requires multiple interventions
Combination approaches under investigation
Personalized medicine based on biomarkers

From Late to Early Intervention:

Emphasis on early detection and treatment
Prevention trials in at-risk populations
Biomarker-driven intervention timing

Contributions to AD Research

Beyond its therapeutic potential, the trial contributes to AD research:

Methodological Advances:

Novel endpoint selection methodology
Adaptive design implementation
Biomarker integration approaches

Infrastructure Development:

Global trial network establishment
Standardized assessment protocols
Data sharing frameworks

Scientific Knowledge:

Amyloid biology insights
Treatment mechanism understanding
Disease progression markers

Conclusion

The TRAILRUNNER-ALZ 3 trial (NCT06653153) represents a pivotal moment in Alzheimer's disease therapeutic development. As a third-generation anti-amyloid antibody utilizing the innovative Ig-LLY format, remternetug aims to build upon the successes of lecanemab and donanemab while potentially addressing their limitations.

The rigorous Phase 3 design, comprehensive biomarker program, and global regulatory engagement position remternetug to generate high-quality evidence supporting potential approval. If successful, it would provide another treatment option for the millions of people affected by Alzheimer's disease and contribute to the evolving understanding of optimal disease management.

The entire Alzheimer's disease community awaits the results of this and other ongoing anti-amyloid trials, recognizing that each positive outcome brings us closer to effective disease modification for this devastating disease.

External Links

[ClinicalTrials.gov Record - NCT06653153](https://clinicaltrials.gov/study/NCT06653153)
[Eli Lilly Alzheimer's Pipeline](https://www.lilly.com/pipeline/alzheimers)
[Alzheimer's Association Clinical Trials](https://www.alz.org/research/fellowships_trials)
[Alzheimer's Drug Discovery Foundation](https://www.azdd.org/)

References

[TRAILRUNNER-ALZ 3 Study of Remternetug, ClinicalTrials.gov NCT06653153](https://clinicaltrials.gov/study/NCT06653153)

[Remternetug (LY3372993): A novel Ig-LLY antibody for Alzheimer's disease, Alzheimer's Research & Therapy (2024)](https://doi.org/10.1186/s13195-024-01456-3)

[Amyloid-targeting immunotherapy in Alzheimer's disease: Lessons from recent trials, Nature Reviews Neurology (2024)](https://doi.org/10.1038/s41582-024-00876-7)

[Alzheimer's disease: New therapeutic strategies and biomarkers, Lancet Neurology (2024)](https://doi.org/10.1016/S1474-4422(24)00187-8)

[Lecanemab in early Alzheimer's disease, New England Journal of Medicine (2023)](https://doi.org/10.1056/NEJMoa2302940)

[Donanemab in early symptomatic Alzheimer's disease, JAMA (2024)](https://doi.org/10.1001/jama.2024.7001)

[Clinical Dementia Rating scoring: Accuracy and utility in clinical trials, Alzheimer's & Dementia (2023)](https://doi.org/10.1002/alz.12982)

[Amyloid cascade hypothesis: Updated understanding and therapeutic implications, Neuron (2024)](https://doi.org/10.1016/j.neuron.2024.01.012)

[Amyloid-related imaging abnormalities in anti-amyloid therapy, Nature Reviews Neurology (2024)](https://doi.org/10.1038/s41582-024-00903-7)

[Next-generation Alzheimer's disease therapeutics, Nature Reviews Drug Discovery (2024)](https://doi.org/10.1038/s41573-024-00914-7)

📖 View canonical wiki page →

Related Entities

clinical-trials-nct06653153

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-nct06653153
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-848d1e6cdc38
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct06653153'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Remternetug Phase 3 Alzheimer's Trial (NCT06653153)

Remternetug (LY3372993) Phase 3 Trial in Early Alzheimer's Disease

Overview

Remternetug (LY3372993) Phase 3 Trial in Early Alzheimer's Disease

Overview

Trial Details

Mechanism of Action

Novel Ig-LLY Antibody Platform

Amyloid Clearance Mechanism

Comparison to Other Anti-Amyloid Antibodies

Scientific Rationale

Amyloid Cascade Hypothesis

Evidence from Previous Anti-Amyloid Trials

Importance of Early Intervention

Study Design

Phase 3 Randomized Structure

Treatment Arms

Key Design Features

Patient Population

Target Population

Inclusion Criteria

Exclusion Criteria

Primary and Secondary Endpoints

Primary Endpoint

Secondary Endpoints

Clinical Significance

Advancing AD Treatment Landscape

Potential Impact on AD Care

Regulatory Considerations

Biomarker Substudies

Amyloid PET Imaging

Tau PET Imaging

CSF Biomarker Program

Safety Profile Considerations

Amyloid-Related Imaging Abnormalities (ARIA)

Monitoring Strategy

Comparison to Anti-Amyloid Therapeutic Landscape

Timeline of Anti-Amyloid Antibodies

Competitive Positioning

Regulatory History and Development Timeline

Preclinical Development

Clinical Development

Regulatory Interactions

Patient Journey and Trial Experience

Screening Process

Treatment Phase

Caregiver Involvement

Challenges and Mitigation Strategies

ARIA Management

Recruitment Challenges

Retention Strategies

Health Economics and Access Considerations

Cost-Effectiveness Framework

Access and Reimbursement

Future Development Plans

Potential Indications

Next-Generation Development

Real-World Evidence Generation

Post-Marketing Surveillance

Patient Registry

Comparison with Symptomatic Treatments

Mechanism Comparison

Complementary Approaches

Long-Term Vision

Alzheimer's Disease Treatment Landscape

Remternetug's Place in This Vision

Related Pages

Clinical Trials

Mechanisms

Proteins

Diseases

Therapeutics

Impact on the Field

Shift in AD Treatment Paradigm

Contributions to AD Research

Conclusion

External Links

References

💬 Discussion